Of the millions of newly diagnosed new cancer patients in the U.S. each year, approximately 30% are diagnosed with non-small cell lung cancer. While cancer is rarely as aggressive as some other types of solid tumors and the survival rate for non-small cell lung cancer can be as high as 85%, new immunotherapy approaches have revolutionized the treatment landscape, leading to a substantial increase in survival even for patients with advanced cancers. However, immunotherapy-mediated inhibition has been a challenge due to unraveling of the receptors involved and the fact that immunotherapy can also cause severe side effects. Now a team of researchers led by ACS, one of the world’s most prominent chemistry journals, has equipped lipids (specific lipids) that bind to the lipids that stimulate the production of inflammatory cytokines to induce NK-cell survival and anti-tumor activity. Approved in advance of implementation by drug companies in response to regulatory and regulatory requests, the work represents a significant advance not only in immunotherapy, but potentially therapeutic approaches to treat non-small cell lung cancer. The study, “Cancer immunotherapies with enhanced release of pro-inflammatory lipids induce NK-cell survival and anti-tumor activity using lipids explained by evolution,” is published in the journal AACC’s ACS Signal Processing & Cytokine Processing. The research was conducted by Thannickalasmaannii (Thanx), a member of the HaloHelix Consortium, a large group of synthetic, single cell and antigenic molecules from Xenobio Research, Inc. and a corporate research and development affiliate of Sansomon Philanthropies, Inc.
